Cancer Sci: Pembrolizumab monototherapy in patients with advanced ovarian cancer in Japan

Interim results of the 2-phase KEYNOTE-100 study (NCT02674061) of 376 patients with advanced recurrentovarian cancer(ROC) in the past showed that the Bloomberg Zuma single drug treatment was associated with an objective response rate of 8.0% CI (95% CI, 5.4-11.2)We presented the results of Japanese patients who participated in THE KEYNOTE-100 (n - 21)epithelial ROC patients had previously received 1-3 chemotherapy lines, with no platinum interval or no treatment interval (PFI; TFI) for 3-12 months (queue A), or 4-6 previous lysis of chemotherapy, and PFI/TFI for 3 months (queue B)All patients receive pembrolizumab 200 mg every 3 weeks for a period of 2 years, or until progression, death, unacceptable toxicity or consent to withdrawThe main targets are ORR per RECIST v1.1 per queue and higher procedural death ligand-1 (PD-L1) tumor expressionAssess the relationship between PD-L1 expression (measured by comprehensive positive score (CPS) and ORR21 Japanese patients (queue A, n s 19; queue B, n s 2) were treatedThe median (range) age was 57 (37-78), 19 (90.5%) had ANECOG status of 0 and 16 (76.2%) had stage III-IV diseaseThe ORR is 19.0% (95% CI, 5.4-41.9), which appears to increase with the expression of PD-L1A total of 13 (61.9%) patients had treatment-related adverse events (TRAE) and 5 (23.8%) had 3-4 levels of TRAEThere were no treatment-related deaths in the subgroupPembrolizumab single drug therapy was associated with anti-tumor activity in Japanese ROC patients, and no new safety signals were found in the subgroupThe data show edified the increased expression of PD-L1 in some patients with higher ORR